173 related articles for article (PubMed ID: 21376394)
1. Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation.
Leon A; Staropoli JF; Hernandez JM; Longtine JA; Kuo FC; Dal Cin P
Leuk Res; 2011 Sep; 35(9):1188-92. PubMed ID: 21376394
[TBL] [Abstract][Full Text] [Related]
2. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
Ohyashiki K; Kodama A; Ohyashiki JH
Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436
[TBL] [Abstract][Full Text] [Related]
3. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
[TBL] [Abstract][Full Text] [Related]
4. JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report.
Yhim HY; Kim HS; Sohn JY; Song MJ; Lee NR; Song EK; Choi SI; Yim CY; Kwak JY
Cancer Genet Cytogenet; 2010 Apr; 198(2):162-5. PubMed ID: 20362232
[TBL] [Abstract][Full Text] [Related]
5. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia.
Hsiao HH; Ito Y; Sashida G; Ohyashiki JH; Ohyashiki K
Leuk Res; 2005 Nov; 29(11):1247-52. PubMed ID: 16164981
[TBL] [Abstract][Full Text] [Related]
6. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.
Gangat N; Tefferi A; Thanarajasingam G; Patnaik M; Schwager S; Ketterling R; Wolanskyj AP
Eur J Haematol; 2009 Jul; 83(1):17-21. PubMed ID: 19236446
[TBL] [Abstract][Full Text] [Related]
8. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
9. Reemergence of JAK2 V617F clone heralds extramedullary leukemia relapse after BMT for transformed essential thrombocytosis.
Au WY; Fung A; Lie AK; Lam KY; Lam CC; Kwong YL
Ann Hematol; 2007 Feb; 86(2):145-7. PubMed ID: 17111143
[No Abstract] [Full Text] [Related]
10. Derivative (1;18)(q10;q10) in essential thrombocythemia.
Azuma T; Yamanouchi J; Inoue K; Kohno M; Narumi H; Fujiwara H; Yakushijin Y; Hato T; Yasukawa M
Cancer Genet Cytogenet; 2010 May; 199(1):62-4. PubMed ID: 20417872
[TBL] [Abstract][Full Text] [Related]
11. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
[TBL] [Abstract][Full Text] [Related]
14. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
15. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
[TBL] [Abstract][Full Text] [Related]
16. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
[TBL] [Abstract][Full Text] [Related]
17. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
18. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A
Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
[TBL] [Abstract][Full Text] [Related]
19. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
20. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
